Aratana Therapeutics Inc. (NASDAQ:PETX) shares traded up 9.2% on Tuesday . The stock traded as high as $9.39 and last traded at $9.34, with a volume of 1,023,652 shares. The stock had previously closed at $8.55.

Several research analysts have recently weighed in on the company. Lake Street Capital restated a “buy” rating and issued a $15.00 price target on shares of Aratana Therapeutics in a research note on Sunday, July 17th. Credit Suisse Group AG reiterated a “buy” rating and set a $11.00 price objective on shares of Aratana Therapeutics in a research report on Wednesday. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.66.

The company has a 50 day moving average price of $7.00 and a 200 day moving average price of $5.70. The company’s market capitalization is $329.36 million.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.37. The business earned $38.05 million during the quarter, compared to analyst estimates of $15.14 million. During the same period in the previous year, the business earned ($0.23) EPS. On average, equities analysts expect that Aratana Therapeutics Inc. will post ($0.81) EPS for the current year.

In other news, CEO Peter Steven St sold 100,000 shares of the firm’s stock in a transaction on Friday, June 17th. The stock was sold at an average price of $6.26, for a total value of $626,000.00. Following the completion of the sale, the chief executive officer now owns 717,793 shares of the company’s stock, valued at approximately $4,493,384.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total value of $187,500.00. Following the completion of the sale, the insider now directly owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.